Cwm LLC Sells 4,352 Shares of Novo Nordisk A/S (NYSE:NVO)

Cwm LLC reduced its position in Novo Nordisk A/S (NYSE:NVO) by 3.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 105,834 shares of the company’s stock after selling 4,352 shares during the quarter. Cwm LLC’s holdings in Novo Nordisk A/S were worth $10,949,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the stock. Westside Investment Management Inc. lifted its stake in shares of Novo Nordisk A/S by 83.3% in the 3rd quarter. Westside Investment Management Inc. now owns 1,428 shares of the company’s stock valued at $130,000 after acquiring an additional 649 shares during the last quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD bought a new stake in Novo Nordisk A/S during the third quarter valued at $2,408,000. Lazard Asset Management LLC boosted its position in shares of Novo Nordisk A/S by 182.2% during the 3rd quarter. Lazard Asset Management LLC now owns 1,494,214 shares of the company’s stock valued at $135,883,000 after purchasing an additional 964,640 shares in the last quarter. Benedict Financial Advisors Inc. lifted its stake in Novo Nordisk A/S by 94.0% in the third quarter. Benedict Financial Advisors Inc. now owns 44,292 shares of the company’s stock valued at $4,028,000 after buying an additional 21,457 shares during the period. Finally, CENTRAL TRUST Co boosted its stake in Novo Nordisk A/S by 111.6% during the third quarter. CENTRAL TRUST Co now owns 6,004 shares of the company’s stock worth $546,000 after acquiring an additional 3,166 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $125.23 on Tuesday. The firm has a market capitalization of $561.97 billion, a P/E ratio of 46.30, a price-to-earnings-growth ratio of 2.05 and a beta of 0.41. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. The business’s fifty day simple moving average is $126.49 and its 200 day simple moving average is $111.28. Novo Nordisk A/S has a 12 month low of $75.56 and a 12 month high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.05. The company had revenue of $9.51 billion during the quarter, compared to analyst estimates of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. As a group, analysts anticipate that Novo Nordisk A/S will post 3.32 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were paid a $0.664 dividend. The ex-dividend date was Friday, March 22nd. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a dividend yield of 0.9%. Novo Nordisk A/S’s payout ratio is presently 49.17%.

Analysts Set New Price Targets

NVO has been the subject of several research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target on the stock. Morgan Stanley began coverage on Novo Nordisk A/S in a report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price objective for the company. Finally, UBS Group initiated coverage on Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating on the stock. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.